The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects
Open accessAbstract
Background: Sodium-glucose cotransporter-2 inhibitors improve heart failure–related outcomes. The mechanisms underlying these benefits are not well understood, but diuretic properties may contribute. Traditional diuretics such as furosemide induce substantial neurohormonal activation, contributing to the limited improvement in intravascular volume often seen with these agents. However, the proximal tubular site of action of the sodium-glucose cotransporter-2 inhibitors may help circumvent these limitations. Methods: Twenty patients with type 2 diabetes mellitus and chronic, stable heart failure completed a randomized, placebo-controlled crossover study of empagliflozin 10 mg daily versus placebo. Patients underwent an intensive 6-hour biospecimen collection and cardiorenal phenotyping at baseline and again after 14 days of study drug. After a 2-week washout, patients crossed over to the alternate therapy with the above protocol repeated. Results: Oral empagliflozin was rapidly absorbed as evidenced by a 27-fold increase in urinary glucose excretion by 3 hours ( P <0.0001). Fractional excretion of sodium increased significantly with empagliflozin monotherapy versus placebo (fractional excretion of sodium, 1.2±0.7% versus 0.7±0.4%; P =0.001), and there was a synergistic effect in combination with bumetanide (fractional excretion of sodium, 5.8±2.5% versus 3.9±1.9%; P =0.001). At 14 days, the natriuretic effect of empagliflozin persisted, resulting in a reduction in blood volume (−208 mL [interquartile range, −536 to 153 mL] versus −14 mL [interquartile range, −282 to 335 mL]; P =0.035) and plasma volume (−138 mL, interquartile range, −379 to 154±453 mL; P =0.04). This natriuresis was not, however, associated with evidence of neurohormonal activation because the change in norepinephrine was superior ( P =0.02) and all other neurohormones were similar ( P <0.34) during the empagliflozin versus placebo period. Furthermore, there was no evidence of potassium wasting ( P =0.20) or renal dysfunction ( P >0.11 for all biomarkers), whereas both serum magnesium ( P <0.001) and uric acid levels ( P =0.008) improved. Conclusions: Empagliflozin causes significant natriuresis, particularly when combined with loop diuretics, resulting in an improvement in blood volume. However, off-target electrolyte wasting, renal dysfunction, and neurohormonal activation were not observed. This favorable diuretic profile may offer significant advantage in the management of volume status in patients with heart failure and may represent a mechanism contributing to the superior long-term heart failure outcomes observed with these agents. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03027960.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citationEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
Francis, G. S., Benedict, C., Johnstone, D. E., Kirlin, P. C., Nicklas, J., Liang, C. S., Kubo, S. H., Rudin-Toretsky, E., & Yusuf, S. (1990) · Circulation · doi:10.1161/01.cir.82.5.1724 · Cited by 1,388
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Gheorghiade, M., Follath, F., Ponikowski, P., Barsuk, J. H., Blair, J. E. A., Cleland, J. G., Dickstein, K., Drazner, M. H., Fonarow, G. C., Jaarsma, T., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq045 · Cited by 739
Rehospitalization for Heart Failure
Gheorghiade, M., Vaduganathan, M., Fonarow, G. C., & Bonow, R. O. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.038 · Cited by 730
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Testani, J. M., Chen, J., McCauley, B. D., Kimmel, S. E., & Shannon, R. P. (2010) · Circulation · doi:10.1161/circulationaha.109.933275 · Cited by 680
Self-citationJohnson, M. H. (1996) · Europe PMC (PubMed Central) · Cited by 651
Gheorghiade, M., & Pang, P. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.041 · Cited by 600
FRANCIS, G. S., SIEGEL, R. M., GOLDSMITH, S. R., OLIVARI, M. T., LEVINE, T. B., & COHN, J. N. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-1-1 · Cited by 579
Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment
Gheorghiade, M., Filippatos, G., De Luca, L., & Burnett, J. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.09.011 · Cited by 426
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1712572 · Cited by 415
Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart Failure
Jentzer, J. C., DeWald, T. A., & Hernandez, A. F. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.034 · Cited by 409
Brenner, B. M. (1996) · Cited by 330
Testani, J. M., Brisco, M. A., Turner, J. M., Spatz, E. S., Bellumkonda, L., Parikh, C. R., & Tang, W. H. W. (2014) · Circulation: Heart Failure · doi:10.1161/circheartfailure.113.000895 · Cited by 296
Self-citationLoop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil?
Felker, G. M., O'Connor, C. M., & Braunwald, E. (2009) · Circulation: Heart Failure · doi:10.1161/circheartfailure.108.821785 · Cited by 296
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1902837 · Cited by 290
Kidokoro, K., Cherney, D. Z. I., Bozovic, A., Nagasu, H., Satoh, M., Kanda, E., Sasaki, T., & Kashihara, N. (2019) · Circulation · doi:10.1161/circulationaha.118.037418 · Cited by 283
Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
SGLT2 Inhibitor–Induced Sympathoinhibition
Herat, L. Y., Magno, A. L., Rudnicka, C., Hricova, J., Carnagarin, R., Ward, N. C., Arcambal, A., Kiuchi, M. G., Head, G. A., Schlaich, M. P., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.11.007 · Cited by 233
Juxtaglomerular cell complex in the regulation of renal salt excretion
Schnermann, J. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.2.r263 · Cited by 231
Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Matthews, V. B., Elliot, R. H., Rudnicka, C., Hricova, J., Herat, L., & Schlaich, M. P. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001434 · Cited by 222
Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018010103 · Cited by 209
Self-citationMechanism of impaired natriuretic response to furosemide during prolonged therapy
Loon, N. R., Wilcox, C. S., & Unwin, R. J. (1989) · Kidney International · doi:10.1038/ki.1989.246 · Cited by 205
Cardiorenal Syndrome in Acute Decompensated Heart Failure
Sarraf, M., Masoumi, A., & Schrier, R. W. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03150509 · Cited by 171
Testani, J. M., Brisco, M. A., Chen, J., McCauley, B. D., Parikh, C. R., & Tang, W. H. W. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.027 · Cited by 167
Self-citationZhang, N., Feng, B., Ma, X., Sun, K., Xu, G., & Zhou, Y. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0914-1 · Cited by 167
Vallon, V., Blantz, R. C., & Thomson, S. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000051700.07403.27 · Cited by 166
Diuretics and Ultrafiltration in Acute Decompensated Heart Failure
Felker, G. M., & Mentz, R. J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.910 · Cited by 165
Škrtić, M., & Cherney, D. Z. I. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000084 · Cited by 156
Miller, W. L., & Mullan, B. P. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.02.007 · Cited by 145
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Wan, N., Rahman, A., Hitomi, H., & Nishiyama, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00421 · Cited by 115
Brisco‐Bacik, M. A., ter Maaten, J. M., Houser, S. R., Vedage, N. A., Rao, V. S., Ahmad, T., Wilson, F. P., & Testani, J. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009149 · Cited by 114
Self-citationYoshimoto, T., Furuki, T., Kobori, H., Miyakawa, M., Imachi, H., Murao, K., & Nishiyama, A. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000445 · Cited by 57
Heart Failure Outcomes With Volume-Guided Management
Strobeck, J. E., Feldschuh, J., & Miller, W. L. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.06.017 · Cited by 57
Use of Diuretics in Heart Failure and Cirrhosis
Schrier, R. W. (2011) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.09.005 · Cited by 35
Shah, S., Pitt, B., Brater, D. C., Feig, P. U., Shen, W., Khwaja, F. S., & Wilcox, C. S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006135 · Cited by 33
Cited by
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
Self-citationPathophysiology of Hypertension: The Mosaic Theory and Beyond
Harrison, D. G., Coffman, T. M., & Wilcox, C. S. (2021) · Circulation Research · doi:10.1161/circresaha.121.318082 · Cited by 365
Nassif, M. E., Qintar, M., Windsor, S. L., Jermyn, R., Shavelle, D. M., Tang, F., Lamba, S., Bhatt, K., Brush, J., Civitello, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052503 · Cited by 281
Curtain, J. P., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab560 · Cited by 256
Self-citation
Metadata
- Authors
- Griffin, M., Rao, V. S., Ivey-Miranda, J., Fleming, J., Mahoney, D., Maulion, C., Suda, N., Siwakoti, K., Ahmad, T., Jacoby, D., Riello, R., Bellumkonda, L., Cox, Z., Collins, S., Jeon, S., Turner, J. M., Wilson, F. P., Butler, J., Inzucchi, S. E., & Testani, J. M.
- Venue
- Circulation
- Published
- 2020-09-15
- Volume
- 142
- Issue
- 11
- Pages
- 1028-1039
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3025899746
- Cited by
- 414
- References
- 43
- FWCI
- 36.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.